154 related articles for article (PubMed ID: 19500965)
1. The old and the new: successful vaccines of the 20th century and approaches to making vaccines for the important diseases of the 21st century.
Poland G; Barrett A
Curr Opin Immunol; 2009 Jun; 21(3):305-7. PubMed ID: 19500965
[No Abstract] [Full Text] [Related]
2. One decade on.
The Lancet Infectious Diseases
Lancet Infect Dis; 2011 Aug; 11(8):579. PubMed ID: 21798456
[No Abstract] [Full Text] [Related]
3. Protective immunity following vaccination: how is it defined?
Amanna IJ; Messaoudi I; Slifka MK
Hum Vaccin; 2008; 4(4):316-9. PubMed ID: 18398296
[TBL] [Abstract][Full Text] [Related]
4. Human immune memory to yellow fever and smallpox vaccination.
Wrammert J; Miller J; Akondy R; Ahmed R
J Clin Immunol; 2009 Mar; 29(2):151-7. PubMed ID: 19052852
[TBL] [Abstract][Full Text] [Related]
5. From empiricism to rational design: a personal perspective of the evolution of vaccine development.
De Gregorio E; Rappuoli R
Nat Rev Immunol; 2014 Jul; 14(7):505-14. PubMed ID: 24925139
[TBL] [Abstract][Full Text] [Related]
6. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design.
D'Argenio DA; Wilson CB
Immunity; 2010 Oct; 33(4):437-40. PubMed ID: 21029955
[TBL] [Abstract][Full Text] [Related]
7. Vaccination markers: designing unique antigens to be added to vaccines to differentiate between natural infection and vaccination.
Root-Bernstein RS
Vaccine; 2005 Mar; 23(17-18):2057-9. PubMed ID: 15755570
[TBL] [Abstract][Full Text] [Related]
8. 12th Annual Conference on Vaccine Research.
O'Brien J
Expert Rev Vaccines; 2009 Sep; 8(9):1139-42. PubMed ID: 19722886
[TBL] [Abstract][Full Text] [Related]
9. Delivery strategies to enhance mucosal vaccination.
Chadwick S; Kriegel C; Amiji M
Expert Opin Biol Ther; 2009 Apr; 9(4):427-40. PubMed ID: 19344280
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunisation: Successful approaches to targeting different tissues.
Ferro VA; Carter KC
Methods; 2006 Feb; 38(2):61-4. PubMed ID: 16442812
[No Abstract] [Full Text] [Related]
11. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies.
Wiser I; Balicer RD; Cohen D
Vaccine; 2007 Jan; 25(6):976-84. PubMed ID: 17074424
[TBL] [Abstract][Full Text] [Related]
12. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines.
Ahmed R; Akondy RS
Immunol Cell Biol; 2011 Mar; 89(3):340-5. PubMed ID: 21301482
[TBL] [Abstract][Full Text] [Related]
13. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations.
Who
Vaccine; 2015 Jan; 33(1):76-7. PubMed ID: 24852721
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis vaccines: the past, present and future.
Wang J; Xing Z
Expert Rev Vaccines; 2002 Oct; 1(3):341-54. PubMed ID: 12901573
[TBL] [Abstract][Full Text] [Related]
15. Mucosal immunization: a review of strategies and challenges.
Patel H; Yewale C; Rathi MN; Misra A
Crit Rev Ther Drug Carrier Syst; 2014; 31(4):273-303. PubMed ID: 25072196
[TBL] [Abstract][Full Text] [Related]
16. [The topicality of return to smallpox vaccination: problems and prospects].
Onishchenko GG; Maksimov VA; Vorob'ev AA; Podkuĭko VN; Mel'nikov SA
Vestn Ross Akad Med Nauk; 2006; (7):32-8. PubMed ID: 16924876
[TBL] [Abstract][Full Text] [Related]
17. FIELD EXPERIENCE WITH COMBINED LIVE MEASLES, SMALLPOX AND YELLOW FEVER VACCINES.
MEYER HM
Arch Gesamte Virusforsch; 1965; 16():365-6. PubMed ID: 14322897
[No Abstract] [Full Text] [Related]
18. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
[TBL] [Abstract][Full Text] [Related]
19. Comment on "trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination".
Belyakov IM; Ahlers JD
J Immunol; 2009 Feb; 182(4):1779; author reply 1779-80. PubMed ID: 19201827
[No Abstract] [Full Text] [Related]
20. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
Front Immunol; 2020; 11():803. PubMed ID: 32457748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
